Cargando…
Dexmedetomidine-mediated regulation of miR-17-3p in H9C2 cells after hypoxia/reoxygenation injury
Patients with heart disease often suffer from ischemia, which can be treated by reperfusion. However, this treatment can lead to the development of ischemia/reperfusion (I/R) injury, an inflammatory condition that can cause further heart damage. Dexmedetomidine (Dex), an α(2)-adrenoceptor agonist, a...
Autores principales: | Yuan, Tianhui, Yang, Zhongqi, Xian, Shaoxiang, Chen, Yang, Wang, Lingjun, Chen, Weitao, Long, Wenjie, Che, Yuanyuan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
D.A. Spandidos
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7388268/ https://www.ncbi.nlm.nih.gov/pubmed/32742334 http://dx.doi.org/10.3892/etm.2020.8775 |
Ejemplares similares
-
Dexmedetomidine attenuates hypoxia/reoxygenation injury in primary neonatal rat cardiomyocytes
por: Peng, Ke, et al.
Publicado: (2017) -
Dexmedetomidine protects cardiomyocytes against hypoxia/reoxygenation injury via multiple mechanisms
por: Cai, Shunv, et al.
Publicado: (2021) -
MiR-499 inhibited hypoxia/reoxygenation induced cardiomyocytes injury by targeting SOX6
por: Shi, Yujie, et al.
Publicado: (2019) -
Astragaloside IV protects human cardiomyocytes from hypoxia/reoxygenation injury by regulating miR-101a
por: Wu, Yang, et al.
Publicado: (2020) -
Protective effects of dexmedetomidine on hypoxia/reoxygenation injury in cardiomyocytes by regulating the CHOP signaling pathway
por: Shi, Xiaoqiao, et al.
Publicado: (2020)